1.
medrxiv; 2021.
Preprint
in English
| medRxiv | ID: ppzbmed-10.1101.2021.02.23.21251915
ABSTRACT
Efficient and accurate assays for the differential diagnosis of COVID-19 and/or influenza (flu) could facilitate optimal treatment for both diseases. Diagnostic performance related to SARS-CoV-2 and Flu A/B detection was characterized for the BD SARS-CoV-2/Flu for BD MAX System (MAX SARS-CoV-2/Flu) multiplex assay in comparison with BD BioGx SARS-CoV-2 Reagents for BD MAX System (BioGx SARS-CoV-2) and the Cepheid Xpert(R) Xpress Flu/RSV (Xpert Flu). Two hundred and thirty-five nasopharyngeal specimens were obtained from external vendors. MAX SARS-CoV-2/Flu had positive percent agreement (PPA) and negative percent agreement (NPA) values for SARS-CoV-2 and Flu A/B that met FDA-EUA acceptance criteria of >95%.